Full Text
PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.

Abstract

Authors

H Catt K Bodger J Kirkham DA Hughes

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×